<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918915</url>
  </required_header>
  <id_info>
    <org_study_id>SYD-101-001</org_study_id>
    <nct_id>NCT03918915</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of SYD-101 in Children With Myopia</brief_title>
  <acronym>STAAR</acronym>
  <official_title>A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sydnexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sydnexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of
      adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of
      developing other eye conditions such as glucoma, cataracts and retinal detachment, which may
      lead to blindness. Early treatment of myopia in children could help slow the condition and
      minimize the risk of complications later in life. This study investigates the use of SYD-101,
      an eye solution, in slowing-down the progression of myopia in children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 5-arm, multicentered, randomized, double-masked, vehicle-controlled study
      conducted in 2 parts.

      Part 1 is the primary treatment period of 3 years, during which participants will receive 1
      of 3 masked medications.

      Part 2 is the randomized withdrawal period of 1 year, during which participants originally
      receiving Vehicle will receive SYD-101, and participants originally receiving SYD-101 will
      receive either Vehicle or SYD-101.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myopic progression &gt;0.75 D (diopters)</measure>
    <time_frame>Month 36</time_frame>
    <description>Proportion of participants with confirmed myopic progression &gt;0.75 D (diopters), based on SE (spherical equivalent) as measured by cycloplegic autorefraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean annual myopic progression</measure>
    <time_frame>Month 36</time_frame>
    <description>Mean annual progression rate of myopia measured in diopters: Spherical Equivalent (SE) as measured by cycloplegic autorefraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of myopia &gt;0.75 D (diopters)</measure>
    <time_frame>Up to 36 months (from date of randomization until date myopia progresses &gt;0.75 D)</time_frame>
    <description>Progression of myopia measured as Spherical Equivalent (SE) via cycloplegic autorefraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in axial length</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>Measured by cycloplegic biometry</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Nearsightedness</condition>
  <condition>Near Sightedness</condition>
  <condition>Near-sightedness</condition>
  <arm_group>
    <arm_group_label>Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye at bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: SYD-101 Dose 1; Part 2: Vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye at bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye at bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: SYD-101 Dose 2; Part 2: Vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop in each eye at bedtime.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Vehicle; Part 2: SYD-101 Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop in each eye at bedtime.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYD-101 Dose 1</intervention_name>
    <description>Sterile topical ophthalmic solution</description>
    <arm_group_label>Part 1: SYD-101 Dose 1; Part 2: SYD-101 Dose 1</arm_group_label>
    <arm_group_label>Part 1: SYD-101 Dose 1; Part 2: Vehicle</arm_group_label>
    <other_name>atropine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYD-101 Dose 2</intervention_name>
    <description>Sterile topical ophthalmic solution</description>
    <arm_group_label>Part 1: SYD-101 Dose 2; Part 2: SYD-101 Dose 2</arm_group_label>
    <arm_group_label>Part 1: SYD-101 Dose 2; Part 2: Vehicle</arm_group_label>
    <arm_group_label>Part 1: Vehicle; Part 2: SYD-101 Dose 2</arm_group_label>
    <other_name>atropine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Sterile topical ophthalmic solution without active ingredient</description>
    <arm_group_label>Part 1: SYD-101 Dose 1; Part 2: Vehicle</arm_group_label>
    <arm_group_label>Part 1: SYD-101 Dose 2; Part 2: Vehicle</arm_group_label>
    <arm_group_label>Part 1: Vehicle; Part 2: SYD-101 Dose 2</arm_group_label>
    <other_name>Control</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myopia of 0.5 D (diopters) to 6.00 D (inclusive) in both eyes.

          -  Astigmatism ≤1.50 D in both eyes.

          -  Anisometropia ≤1.00 D in both eyes.

          -  If myopia is ≥0.75 D, participant must be wearing single vision eyeglasses or soft,
             daily-wear, single-vision contact lenses that meet study investigator's criteria.

          -  BCVA (best-corrected visual acuity) Snellen equivalent of 20/32 or better.

        Exclusion Criteria:

          -  Participants with a history or current evidence of a medical condition predisposing
             them to degenerative myopia (e.g. Marfan syndrome, Stickler syndrome), or a condition
             that may affect visual function or development (e.g. diabetes mellitus, chromosome
             anomaly).

          -  Current use of a monoamine oxidase inhibitor.

          -  Evidence of any ocular inflammation or infection in either eye, including blepharitis,
             conjunctivitis, keratitis, and scleritis.

          -  Past, present or future plans to use orthokeratology (orthoK), rigid gas-permeable,
             bifocal, progressive-addition, multi-focal, or other lenses to reduce myopia
             progression; or the use of atropine, pirenzepine or other anti-muscarinic agent for
             myopia.

          -  History or evidence of ocular surgery or planned future ocular surgery in either eye.

        Other protocol-defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email:</phone>
    <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site 143</name>
      <address>
        <city>Irwindale</city>
        <state>California</state>
        <zip>91706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 144</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 148</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 133</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 130</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 100</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 150</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 119</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 122</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site 120</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 124</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 116</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>Wilmette</city>
        <state>Illinois</state>
        <zip>60091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 135</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 131</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 137</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 138</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 123</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <zip>63090</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 132</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 139</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 127</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 117</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 121</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 147</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sie 136</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004-1108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Plase contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 128</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 126</name>
      <address>
        <city>Lakeway</city>
        <state>Texas</state>
        <zip>78734</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 142</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 115</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 149</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 140</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 203</name>
      <address>
        <city>Linz</city>
        <state>Oberosterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUSt contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 204</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 205</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 202</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 201</name>
      <address>
        <city>Trebišov</city>
        <zip>075 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Site 200</name>
      <address>
        <city>Trenčín</city>
        <zip>91108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Please contact site directly. Subject line of the email MUST contain NCT 03918915 and Site#</last_name>
      <email>SYDNEXISSYD101001ClinicalTrial.sm@ppdi.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Myopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

